Acute myeloid leukemia · 7 regimens
Cost vs Efficacy
| Regimen | Biomarker | Cost/cycle ↓ | Cycle | PFS ↕ | OS ↕ | Est. cycles | Course cost ↕ | Evidence |
|---|---|---|---|---|---|---|---|---|
Azacitidine and Sorafenib Variant #01 | FLT3 | R 72 005 | 56d | — | — | ~2 | ~R 144 010 indirect | — |
FLAG-Ida Variant #01 | FLT3 | R 48 325 | 28d | — | 5.4 mo | 1 | R 48 325 PFS proxy | 3 |
Azacitidine monotherapy Variant #01 | FLT3 | R 29 332 | 28d | — | ~8.7 mo | ~6 | ~R 175 992 PFS proxy · indirect | 11 |
MEC Variant #01 | FLT3 | R 9 564 | 28d | — | 5.4 mo | 1 | R 9 564 PFS proxy | 3 |
Low-dose Cytarabine monotherapy (LoDAC) Variant #01 | FLT3 | R 1 249 | 28d | — | 4.7 mo | 6 | R 7 491 PFS proxy | 1 |
Gilteritinib monotherapy Variant #01 Partial | FLT3 | — | 28d | — | 9.6 mo | 2 | — | 1 |
Quizartinib monotherapy Variant #01 Partial | FLT3 | — | 28d | — | ~6.2 mo | ~35 | — | 1 |
7 of 7 regimens shown